Three independent discounted-cash-flow-style models value REGENXBIO Inc. every trading day. 0 of 3 currently price RGNX above its market price.
| Free Cash Flow model | $-89.62 |
| Excess Profit model | $-115.04 |
| Residual Earnings model | $-0.08 |
| Dividend Discount model | — |
| Piotroski F-Score | 3 / 9 |
| Return on invested capital | -57.9% |
| Net debt / EBITDA | — |
| Gross margin | +100.0% |
| Revenue CAGR | +14.8% |
| Cash conversion | — |
| Dividend yield | — |
| Buyback yield | -4.2% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open RGNX in StockKitty